Clavam 625 vs Augmentin 625: Amoxicillin-Clavulanic Acid Brand Equivalence
Detailed clinical comparison of Clavam 625 (Alkem) and Augmentin 625 (GSK): Amoxicillin + Clavulanate beta-lactamase inhibitor, bacterial efficacy, and...
Clavam 625 (Alkem Laboratories) and Augmentin 625 Duo (GlaxoSmithKline) contain the identical combination of Amoxicillin 500mg + Potassium Clavulanate 125mg. Both are frontline co-amoxiclav antibiotics for acute bacterial sinusitis, bronchitis, skin infections, and dental abscesses. They share identical clinical efficacy and safety profiles.
1. Brand Comparison and Market Standing
GSK developed the original innovator formulation (Augmentin), while Alkem's Clavam is one of the highest-prescribed domestic formulations in India. Both utilize identical high-grade active ingredients verified under Indian Pharmacopoeia standards.
2. Moisture Barrier & Strip Handling
Potassium clavulanate is exceptionally sensitive to ambient atmospheric humidity, degrading rapidly into brown, inactive products if exposed to air. Both brands use heavy Alu-Alu strip packaging; keep tablets sealed until the exact moment of consumption.
3. Jan Aushadhi Generic Savings
Branded Augmentin 625 costs ~₹220 for 10 tablets, and Clavam 625 costs ~₹200. At Jan Aushadhi Kendras, certified Amoxicillin 500mg + Clavulanic Acid 125mg tablets cost ₹58.00 (74% savings).
Top 8 Essential Indian Medicines: Branded MRP vs. Jan Aushadhi Generic Comparison
Compare average Indian retail MRP of top branded formulations against government-certified PMBJP Jan Aushadhi bioequivalent generic prices and active salts. Verified against official PMBJP formularies, NPPA price caps, and CDSCO regulatory registries.
| Brand Name | Leading Manufacturer | Active Salt Formulation (IP) | Branded MRP | Jan Aushadhi Price | Savings % |
|---|---|---|---|---|---|
| Augmentin 625 Duo | GlaxoSmithKline Pharmaceuticals | Amoxicillin Trihydrate 500mg + Potassium Clavulanate 125mg IP | ₹220.00 | ₹58.00 | 74% |
| Dolo 650 | Micro Labs Ltd | Paracetamol (Acetaminophen) 650mg IP | ₹34.00 | ₹5.50 | 84% |
| Pantocid 40 | Sun Pharmaceutical Industries | Pantoprazole Sodium 40mg IP (Gastro-resistant) | ₹155.00 | ₹8.00 | 95% |
| Azithral 500 | Alembic Pharmaceuticals | Azithromycin Dihydrate 500mg IP | ₹132.00 | ₹24.00 | 82% |
| Glycomet 500 | USV Private Limited | Metformin Hydrochloride 500mg IP | ₹24.00 | ₹4.50 | 81% |
| Shelcal 500 | Torrent Pharmaceuticals | Elemental Calcium 500mg + Cholecalciferol (Vit D3) 250 IU IP | ₹134.00 | ₹16.00 | 88% |
| Telma 40 | Glenmark Pharmaceuticals | Telmisartan 40mg IP | ₹92.00 | ₹7.50 | 92% |
| Montair-LC | Cipla Ltd | Montelukast Sodium 10mg + Levocetirizine Dihydrochloride 5mg IP | ₹210.00 | ₹18.00 | 91% |
| Combined 8-Drug Essential Therapy Basket Total: | ₹1,001.00 | ₹141.00 | 85.9% Net Savings | ||
Frequently Asked Questions (Clinical & Regulatory)
Q1: Why do doctors prescribe Clavam 625 instead of plain Amoxicillin?
Many bacterial pathogens produce beta-lactamase enzymes that destroy plain amoxicillin. Clavulanate in Clavam neutralizes these enzymes, allowing amoxicillin to work.
Q2: Can I take Clavam 625 twice daily (BD)?
Yes, standard adult dosing for moderate-to-severe bacterial infections is 1 tablet every 12 hours (BD) for 5 to 7 days.
Q3: How does the CDSCO define bioequivalence when comparing two pharmaceutical formulations?
Bioequivalence is confirmed when two pharmaceutical products contain identical active therapeutic moieties and show no statistically significant difference in Cmax and AUC under single-dose fasting and fed pharmacokinetic studies within the 80% to 125% confidence interval.
Q4: When comparing two drugs in the same clinical class, what determines superior therapeutic choice?
Therapeutic selection depends on receptor selectivity, onset speed, elimination half-life, clearance pathway (hepatic CYP450 vs renal excretion), drug interaction liability, and clinical trial evidence regarding organ-specific outcomes.
Q5: Can patients interchange two bioequivalent branded formulations without loss of efficacy?
Yes. Formulations produced under Schedule M Good Manufacturing Practices containing identical active pharmaceutical salts and dissolution profiles can be interchanged safely under pharmacist guidance.
This clinical guide is authored and reviewed in accordance with the regulatory standards of the Indian Pharmacopoeia (IP), Central Drugs Standard Control Organization (CDSCO) drug schedules, and Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) bioequivalence guidelines. All therapeutic recommendations and drug interaction warnings are cross-referenced with official statutory publications.
Under India's Digital Personal Data Protection (DPDP) Act, 2023, MediMatch AI functions as a data fiduciary committed to zero retention of private health identifiers. Browsing educational guides, reviewing active salt monographs, and executing search queries occur without tracking or commercial profiling. All client interactions with prescription readers or lab decoders execute ephemerally in volatile memory with zero server-side storage of protected health information (PHI). For inquiries regarding data fiduciary obligations, contact our Data Protection Officer at privacy@medimatchai.in.